[{"address1": "3300 Bee Cave Road", "address2": "Suite 650-227", "city": "Austin", "state": "TX", "zip": "78746", "country": "United States", "phone": "877-774-4679", "website": "https://www.genprex.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.", "fullTimeEmployees": 26, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark S. Berger M.D.", "age": 68, "title": "Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 528157, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David M. Schloss", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas C. Gallagher Esq.", "title": "Senior Vice President of Intellectual Property & Licensing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suzanne  Thornton-Jones", "title": "Senior Vice President of Regulatory Affairs & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.735, "open": 2.69, "dayLow": 2.41, "dayHigh": 2.69, "regularMarketPreviousClose": 2.735, "regularMarketOpen": 2.69, "regularMarketDayLow": 2.41, "regularMarketDayHigh": 2.69, "beta": -0.54, "forwardPE": -0.90405905, "volume": 84361, "regularMarketVolume": 84361, "averageVolume": 114963, "averageVolume10days": 463780, "averageDailyVolume10Day": 463780, "bid": 2.38, "ask": 2.56, "bidSize": 100, "askSize": 100, "marketCap": 5141815, "fiftyTwoWeekLow": 2.09, "fiftyTwoWeekHigh": 42.0, "fiftyDayAverage": 2.52852, "twoHundredDayAverage": 8.29158, "currency": "USD", "enterpriseValue": -1951974, "floatShares": 1898386, "sharesOutstanding": 2098700, "sharesShort": 49962, "sharesShortPriorMonth": 69946, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0238, "heldPercentInsiders": 0.01672, "heldPercentInstitutions": 0.068179995, "shortRatio": 1.47, "shortPercentOfFloat": 0.0241, "impliedSharesOutstanding": 2232980, "bookValue": 4.991, "priceToBook": 0.4908836, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -30860460, "trailingEps": -18.81, "forwardEps": -2.71, "lastSplitFactor": "1:40", "lastSplitDate": 1706832000, "enterpriseToEbitda": 0.063, "52WeekChange": -0.93399787, "SandP52WeekChange": 0.23232913, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNPX", "underlyingSymbol": "GNPX", "shortName": "Genprex, Inc.", "longName": "Genprex, Inc.", "firstTradeDateEpochUtc": 1522330200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d506e914-dc7c-30af-b5b9-638e83c34981", "messageBoardId": "finmb_225557674", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.45, "targetHighPrice": 320.0, "targetLowPrice": 10.0, "targetMeanPrice": 165.0, "targetMedianPrice": 165.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 6737629, "totalCashPerShare": 3.527, "ebitda": -31060566, "quickRatio": 2.07, "currentRatio": 2.314, "returnOnAssets": -1.08639, "returnOnEquity": -2.07877, "freeCashflow": -13901023, "operatingCashflow": -24738604, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-10"}]